N1048: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (H-32928 (VA, H-32929))
N1048 (PROSPECT): A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (H-32928, VA-H-32929)
This study will investigate how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. Patients must have a diagnosis of locally advanced rectal adenocarcinoma and have not received any prior radiation therapy or any chemotherapy within 5 years. Patients will be randomized to one of two treatment arms to receive chemotherapy alone or chemotherapy plus radiation followed by surgery.
For more information: http://clinicaltrials.gov/show/NCT01515787